Routine immunization profile: Denmark

*Up until April 2017 ** From April 2017 ***Second dose +5M Routine immunization profile Denmark Progress towards achieving European Vaccine Action Plan goals, 2017 Goal Indicator Status Goal Indicator Status 1 Sustain polio-free status a (Current risk) Yes (Low) 4 Meets vaccination coverage targets DTP3 national immunization coverage ≥95%d ≥90% DTP3 coverage achieved in ≥90% of districtse Yes Yes Yes 2 Measles elimination statusb Eliminated 5 Make evidence-based decisions about introduction of new vaccines*e NITAG made a recommendation about PCV NITAG made a recommendation about RV NITAG made a recommendation about HPV Yes Yes Yes YesRubella elimination status b Endemic 3 Control hepatitis B infectionc Validation pending 6 Achieve financial sustainability of the national immunization programme**c Yes *New vaccines introduced or not introduced based on NITAG evidence-based recommendations **Country self-sufficient for procuring routine vaccines Demographic, income and health expenditure summary, 2017 Total Populationf 5 733 551 Live births 60 616 Surviving infants 60 433 <5 years 285 454 <15 years 945 187 Neonatal mortality rate (per 1000 live births)f 3.1 Infant mortality rate (per 1000 live births)f 3.7 Number of districtse 11 GNI (per capita, in USD)g 55 330 Health spending as % of total government expenditureg 16 Immunization schedule, 2017e 3M DTaPHibHepBIPV*, DTaPHibIPV**, PCV 5M DTaPHibHepBIPV*, DTaPHibIPV**, PCV 12M DTaPHibHepBIPV*, DTaPHibIPV**, PCV 15M MMR 4Y MMR 5Y TdaPIPV 12Y HPV*** Routine immunization profile Denmark Vaccine coverage estimates, 2013-2017d Number of reported cases of vaccine- preventable diseases, 2013-2017e 2013 2014 2015 2016 2017 Measles 17 27 9 3 4 Mumps 60 41 15 15 11 Rubella 0 ND ND 0 0 Congenital rubella syndrome 0 ND 0 0 0 Diphtheria 0 ND 1 ND 1 Tetanus 1 ND ND ND 2 Pertussis 484 855 962 2096 1081 Hepatitis A 102 28 19 37 38 Varicella NR ND ND ND NR DTP3 reported coverage by subnational area†, 2017e MCV2 reported coverage by subnational area†, 2017eMCV1 reported coverage by subnational area†, 2017e Surveillance with laboratory confirmation of cases, 2017e Measles Yes Rubella No Congenital rubella syndrome Yes Rotavirus No Invasive meningococcal disease Yes Invasive pneumococcal disease Yes Invasive Haemophilus influenzae disease Yes Note: Case-based surveillance (with laboratory confirmation of cases) assessed for measles, rubella, and congenital rubella syndrome. Hospital-based sentinel surveillance and/or population-based surveillance (both with laboratory confirmation of cases) assessed for rotavirus, invasive meningococcal disease, invasive pneumococcal disease, and invasive Haemophilus influenzae disease. ≥95% 90-94% 80-89% <80% ND ≥95% 90-94% 80-89% <80% ND ≥95% 90-94% 80-89% <80% ND ND NR50 0100 2013 2014 2015 2016 2017 BCG NR NR NR NR NR HepB-BD NR NR NR NR NR DTP1 97 96 96 97 99 DTP3 94 94 93 94 98 HepB3 ND ND ND ND ND Hib3 94 94 93 94 98 Pol3 94 94 93 94 98 PCV3 90 93 91 94 97 Rotac NR NR NR NR NR RCV1 89 90 91 94 97 MCV1 89 90 91 94 97 MCV2 86 84 80 85 88 Routine immunization profile Denmark Number of reported measles, mumps and rubella casese and MCV coverage estimatesd, 2013-2017 DTP1-DTP3 dropout rate, 2013-2017d Note: Dropout rate is calculated using WUENIC Reported target population, reported number of DTP3 doses administered and DTP3 reported coveragee, 2013-2017 Number of reported diphtheria, tetanus and pertussis casese and DTP3 coverage estimatesd, 2013-2017 Percentage of districts by DTP3 reported coveragee, 2013-2017 Immunization system characteristics, 2017 Sustained access to WHO accredited polio, measles, and rubella laboratoriesh Yes NITAG in place that meets six WHO criteriae Yes National system in place to monitor AEFIse Yes Communication plan in place to respond to vaccine safety-related eventse Yes Vaccine hesitancy assessment performed within last 5 years e Yes Mandatory proof of immunization at school entrye No Note: The six WHO NITAG criteria are 1. legislative or administrative basis for the advisory group; 2. formal written terms of reference; 3. at least five different areas of expertise represented among core members; 4. at least one meeting per year; 5. circulation of the agenda and background documents at least one week prior to meetings; 6. mandatory disclosure of any conflict of interest 0 20 40 60 80 100 0 10 20 30 40 50 60 70 2013 2014 2015 2016 2017 % c ov er ag e N um be r o f c as es Year Measles Mumps Rubella MCV1 coverage MCV2 coverage 0 20 40 60 80 100 0 500 1000 1500 2000 2500 2013 2014 2015 2016 2017 % c ov er ag e N um be r o f c as es Year Diptheria Tetanus Pertussis DTP3 coverage 0 20 40 60 80 100 0 10000 20000 30000 40000 50000 60000 70000 2013 2014 2015 2016 2017 % c ov er ag e N um be r Year DTP3 reported population DTP3 reported doses DTP3 reported coverage 91 100 64 100 100 9 36 0 20 40 60 80 100 2013 2014 2015 2016 2017 Percentage of subnational areas Ye ar ≥90% 80-89% 50-79% <50% ND 3 2 3 3 1 0 1 2 3 4 5 2013 2014 2015 2016 2017 DTP1-DTP3 dropout rate (%) Ye ar Note: Dropout rate is calculated using WUENIC Routine immunization profile Denmark Vaccine stockouts by administrative levele, 2013-2017 Abbreviations Data sources *Data on HPV stockouts have only been collected in JRF since 2016 a European Regional Commission for Certification of Poliomyelitis eradication (RCC) meeting report: www.euro.who.int/32ndRCC b European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thRVC c European Vaccine Action Plan 2015-2020 Midterm report d WHO/UNICEF Estimates of National Immunization Coverage (WUENIC): (http://www.who.int/immunization/monitoring_surveillance/data/en/) e WHO/UNICEF Joint Reporting Form on immunization (JRF) f World Population Prospects: The 2017 Revision, New York, United Nations g World Bank, World Development Indicators h Polio Laboratory Network: www.euro.who.int/poliolabnetwork & Personal communication based on annual accreditation process of the European Measles and Rubella Laboratory Network † The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Map disclaimer AEFI Adverse event following immunization MCV1 measles-mumps-rubella vaccine, first dose BCG Bacille Calmette-Guerin vaccine for tuberculosis MCV2 measles-mumps-rubella vaccine, second dose CRS congenital Rubella Syndrome MMR measles-mumps-rubella vaccine DT diptheria-tetanus-containing vaccine ND Data not available DTP diptheria-tetanus-pertussis-containing vaccine NITAG National Immunization Technical Advisory Group DTP1 diphtheria-tetanus-pertussis-containing vaccine, first dose NR Not relevant as vaccine not included in immunization schedule DTP3 diphtheria-tetanus-pertussis-containing vaccine, third dose OPV oral polio vaccine GNI Gross national income PCV pneumococcal conjugate vaccine HepB hepatitis B PCV3 pneumococcal conjugate vaccine , third dose HepB3 hepatitis B vaccine, third dose Pol3 polio-containing vaccine, third dose HepB-BD hepatitis B vaccine, birth dose RCV1 rubella-containing vaccine, first dose Hib Haemophilus influenzae type b Rotac rotavirus vaccine-complete series Hib3 Haemophilus influenzae type b vaccine, third dose Td tetanus-diphtheria-containing vaccine HPV human papillomavirus TT tetanus toxoid vaccine IPV inactivated polio vaccine W,M,Y Weeks, Months, Years MCV measles-containing vaccine No stockout Subnational level stockout only National level stockout only Stockout at both levels NR ND 2013 2014 2015 2016 2017 BCG NR NR NR NR NR DTP No No National No National HepB No No No No No Hib No No National No No Pneumo No No No No No Rota NR NR NR NR NR OPV NR NR NR NR NR IPV No No No No No Measles No No No No No HPV * * * No No TT NR No No No NR ©World Health Organization 2019